ARTES showing ‘white biotechnology’ advantages at Jülich Biotech Day

Langenfeld, Germany: – ARTES Biotechnology, the German-based biopharmaceutical CDMO specializing in development of microbial cell lines and production processes for recombinant peptides, proteins and vaccines, will participate in this year’s Jülich Biotech Day dedicated to the implications of White Biotechnology for a post-fossil fuel world.

White biotechnology is focused on a future in which fossil fuels will no longer be used for the production of industrial and consumer goods; goods that people need today. White biotechnology makes use of the properties of yeasts, moulds, bacteria and plants, as well as the enzymes and proteins obtained from them, to manufacture products for everyday use. The manufacturing processes can be carried out with less energy and produce less waste.

Future technologies

The Jūlich Biotech Days are held annually at the Jülich Forschungszentrum campus between Aachen and Mönchengladbach in far western Germany. This is one of Europe’s largest interdisciplinary research centers, where researchers from all over the world work on major future fields of energy, information and bioeconomy.

ARTES will participate as an exhibitor and show how its platform technologies find applications in White biotechnology.

First come first served

As the first commercial samples of our recombinant human serum albumin are now available, we can provide interested parties with free vials for testing.

The rHSA was manufactured and produced in co-operation with ARTES´ dutch partner BasicPharma, as recently announced.

Get your first free vial when you visit BioTechDay! Only while stocks last!

About ARTES Biotechnology

ARTES Biotechnology GmbH is a German company specialized in the development of processes for the production of recombinant proteins from microbial expression systems. In particular, the company offers the development of optimized production cell lines and processes based on yeast (Hansenula, Pichia, Saccharomyces) and bacteria (E. coli). The expression platforms are complemented by a unique virus-like particle (VLP) technology for antigen presentation and vaccine development. For more than 20 years, ARTES has successfully partnered with human and animal health companies, enzyme manufacturers, and the cosmetics, diagnostics, and nutrition industries. The company operates worldwide from its 945 sqm facility in Langenfeld, Germany.

More information at http://www.artes-biotechnology.com

About Jülich Biotech Day 2024

The annual Jülich Biotech Day provides a platform for experts from academia and industry to present current highlights and trends in the exciting research and development field of white biotechnology – using sustainable organic matter to synthesize products currently obtained from fossil fuels.

White biotechnology bridges the gap between sustainable natural resources and valuable chemical products and thus plays a central role in building up a future knowledge-based bioeconomy.

The 2024 Jülich Biotech Day is a one-day event on November 22, hosted as a conference in the central library of the Forschungszentrum Jülich (Jülich Research Center) that is located close to Aachen and Cologne on Germany’s western border with Belgium.

The conference will feature seven presentations on leading-edge white biotechnologies from industrial and academic researchers, as well as a co-located exhibition.

The event is organized by Forschungszentrum Jülich with further information here.

Resources

Click on ARTES Biotechnology Vaccines and Biopharmaceuticals to see introductory video.